Dirk M. Hermann

Effects of pinealectomy and melatonin on the retrograde degeneration of retinal ganglion cells in a novel model of intraorbital optic nerve transection in mice.

Intravenous TAT-Bcl-Xl is protective after middle cerebral artery occlusion in mice.

Adenovirus-mediated Bcl-X(L) expression using a neuron-specific synapsin-1 promoter protects against disseminated neuronal injury and brain infarction following focal cerebral ischemia in mice.

Sleep-disordered breathing and stroke.

Sleep Apnea and Other Sleep-Wake Disorders in Stroke.

Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator.

Intravenously administered recombinant tissue-plasminogen activator attenuates neuronal injury after mild focal cerebral ischemia in mice.

Prophylactic use of melatonin protects against focal cerebral ischemia in mice: role of endothelin converting enzyme-1.

VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena.

Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence.

Erythropoietin protects from axotomy-induced degeneration of retinal ganglion cells by activating ERK-1/-2.

Signal transduction pathways involved in melatonin-induced neuroprotection after focal cerebral ischemia in mice.

Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.

Reversible opsoclonus after diphenhydramine misuse.

Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1/-2 and STAT-1.

Tissue-plasminogen activator-induced ischemic brain injury is reversed by melatonin: role of iNOS and Akt.

Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1/-2 and Akt pathways.

Blood pressure evolution after acute ischemic stroke in patients with and without sleep apnea.

TAT fusion proteins against ischemic stroke: current status and future perspectives.

Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia.

TAT-GDNF in neurodegeneration and ischemic stroke.

The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia.

Tissue plasminogen activator-induced ischemic injury is reversed by NMDA antagonist MK-801 in vivo.

Increased balloon-induced inflammation, proliferation, and neointima formation in apolipoprotein E (ApoE) knockout mice.

Role of drug efflux carriers in the healthy and diseased brain.

Sleep EEG changes after middle cerebral artery infarcts in mice: different effects of striatal and cortical lesions.

Human vascular endothelial growth factor protects axotomized retinal ganglion cells in vivo by activating ERK-1/2 and Akt pathways.

Central periodic breathing during sleep in acute ischemic stroke.

Implications of ATP-binding cassette transporters for brain pharmacotherapies.

Neural stem/precursor cells for the treatment of ischemic stroke.

Tissue plasminogen activator-induced reperfusion injury after stroke revisited.

Acute and chronic exposure to hypoxia alters ventilatory pattern but not minute ventilation of mice overexpressing erythropoietin.

Neuroprotection in the SAINT-II aftermath.

Poxvirus-derived cytokine response modifier A (CrmA) does not protect against focal cerebral ischemia in mice.

Evolution of neurological, neuropsychological and sleep-wake disturbances after paramedian thalamic stroke.

Protein phosphatase 1-dependent bidirectional synaptic plasticity controls ischemic recovery in the adult brain.

Biodistribution processes as underestimated confounders in translational stroke research.

Delayed melatonin administration promotes neuronal survival, neurogenesis and motor recovery, and attenuates hyperactivity and anxiety after mild focal cerebral ischemia in mice.

TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration.

New targets of neuroprotection in ischemic stroke.

Gamma-hydroxybutyrate accelerates functional recovery after focal cerebral ischemia.

ABCC1: a gateway for pharmacological compounds to the ischaemic brain.

Therapeutic potential and possible risks of pleiotropic growth factors in ischemic stroke.

Correspondence (letter to the editor): Blunt Projections.

Delayed post-ischaemic neuroprotection following systemic neural stem cell transplantation involves multiple mechanisms.

Enhancing the delivery of erythropoietin and its variants into the ischemic brain.

Sleep-related breathing and sleep-wake disturbances in ischemic stroke.

Role of Nogo-A in neuronal survival in the reperfused ischemic brain.

Combination of tissue-plasminogen activator with erythropoietin induces blood-brain barrier permeability, extracellular matrix disaggregation, and DNA fragmentation after focal cerebral ischemia in mice.

Animal models of ischemic stroke. Part two: modeling cerebral ischemia.

Animal models of ischemic stroke. Part one: modeling risk factors.

Apolipoprotein E controls ATP-binding cassette transporters in the ischemic brain.

Sleep and stroke.

Nonhematopoietic variants of erythropoietin in ischemic stroke: need for step-wise proof-of-concept studies.

Acute hepatocyte growth factor treatment induces long-term neuroprotection and stroke recovery via mechanisms involving neural precursor cell proliferation and differentiation.

Future Perspectives for Brain Pharmacotherapies: Implications of Drug Transport Processes at the Blood-brain Barrier.

Post-acute delivery of erythropoietin induces stroke recovery by promoting perilesional tissue remodelling and contralesional pyramidal tract plasticity.

ATP-binding cassette transporters and their roles in protecting the brain.

Free radical scavengers and spin traps--therapeutic implications for ischemic stroke.

Liver X receptor activation enhances blood-brain barrier integrity in the ischemic brain and increases the abundance of ATP-binding cassette transporters ABCB1 and ABCC1 on brain capillary cells.

Enhancement of endogenous neurogenesis in ephrin-B3 deficient mice after transient focal cerebral ischemia.

Bringing drugs into the injured brain and keeping them there.

ATP-binding cassette transporters at the blood-brain barrier in ischaemic stroke.

Increased blood-brain barrier permeability and brain edema after focal cerebral ischemia induced by hyperlipidemia: role of lipid peroxidation and calpain-1/2, matrix metalloproteinase-2/9, and RhoA overactivation.

Evidence that membrane-bound G protein-coupled melatonin receptors MT1 and MT2 are not involved in the neuroprotective effects of melatonin in focal cerebral ischemia.

The ATP-binding cassette transporters ABCB1 and ABCC1 are not regulated by hypoxia in immortalised human brain microvascular endothelial cells.

Vascular endothelial growth factor induces contralesional corticobulbar plasticity and functional neurological recovery in the ischemic brain.

Visualization of macroscopic cerebral vessel anatomy--a new and reliable technique in mice.

Intracerebroventricularly delivered VEGF promotes contralesional corticorubral plasticity after focal cerebral ischemia via mechanisms involving anti-inflammatory actions.

Apolipoprotein-E controls adenosine triphosphate-binding cassette transporters ABCB1 and ABCC1 on cerebral microvessels after methamphetamine intoxication.

Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation.

Reelin depletion is an early phenomenon of Alzheimer's pathology.

Transduction of neural precursor cells with TAT-heat shock protein 70 chaperone: therapeutic potential against ischemic stroke after intrastriatal and systemic transplantation.

Effects of vascular endothelial growth factor in ischemic stroke.

Intima-media thickness predicts stroke risk in the Heinz Nixdorf Recall study in association with vascular risk factors, age and gender.

The abluminal endothelial membrane in neurovascular remodeling in health and disease.

A study on the effect of JNK inhibitor, SP600125, on the disruption of blood-brain barrier induced by methamphetamine.

Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.

The novel proteasome inhibitor BSc2118 protects against cerebral ischaemia through HIF1A accumulation and enhanced angioneurogenesis.